2、板块概念方面，虚拟电厂、足球、铜高速连接、CPO等板块领涨；黄金珠宝、美容护理、创新药、 食品饮料等板块领跌； 3、两市共2029只个股上涨，54只个股涨停；2876只个股下跌，6只个股跌停；16只股票炸板，炸板率 31%。 1、市场早间窄幅震荡，三大指数小幅上涨。虚拟电厂概念股走强，恒实科技、金智科技、积成电子等 多股涨停。足球概念股延续强势，金陵体育、共创草坪、舒华体育等涨停。算力硬件股再度走强，天津 普林、广合科技涨停，胜宏科技涨超9%创新高。下跌方面，大消费股集体调整，曼卡龙跌超10%。个 股跌多涨少，沪深京三市超3000股飘绿，上午半天成交7286亿。午间收盘沪指涨0.08%，深成指涨 0.16%，创业板涨0.32%。 ...

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: BioCryst Pharmaceuticals (BCRX) - BioCryst Pharmaceuticals currently holds a Momentum Style Score of B, indicating a favorable momentum characteristic [2] - The company has a Zacks Rank of 1 (Strong Buy), suggesting strong potential for outperformance in the market [3] Performance Metrics - BCRX shares have increased by 1.51% over the past week, while the Zacks Medical - Drugs industry remained flat during the same period [5] - Over the last month, BCRX's price change is 8.96%, outperforming the industry's 3.76% [5] - In the past quarter, BCRX shares have surged by 48.41%, and over the last year, they have gained 66.02%, compared to the S&P 500's increases of 2.37% and 14.4%, respectively [6] Trading Volume - The average 20-day trading volume for BCRX is 4,994,540 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the last two months, 6 earnings estimates for BCRX have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from -$0.06 to $0.16 [9] - For the next fiscal year, 6 estimates have also moved upwards without any downward revisions [9] Conclusion - Considering the positive performance metrics and earnings outlook, BCRX is positioned as a 1 (Strong Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [11]

Group 1 - Cencora (COR) is a notable stock in the Medical sector, currently outperforming the sector with a year-to-date return of 29.6% compared to an average loss of 5.3% for the Medical group [4][5] - Cencora holds a Zacks Rank of 2 (Buy), indicating positive analyst sentiment and an improving earnings outlook, with a 2.9% increase in the consensus estimate for full-year earnings over the past 90 days [3] - The Medical group ranks 4 within the Zacks Sector Rank, which includes 16 different groups, highlighting the relative strength of this sector [2] Group 2 - Cencora is part of the Medical Services industry, which consists of 58 stocks and currently ranks 68 in the Zacks Industry Rank, with an average loss of 3.9% year-to-date [5] - Catalyst Pharmaceutical (CPRX), another stock in the Medical sector, has also outperformed the sector with a year-to-date return of 19.6% and holds a Zacks Rank of 2 (Buy) [4][6] - The Medical - Drugs industry, which includes Catalyst Pharmaceutical, ranks 55 and has experienced a decline of 1.8% so far this year [6]

Investors in Aurinia Pharmaceuticals Inc. (AUPH) need to pay close attention to the stock based on moves in the options market lately. That is because the July 18, 2025 $2.00 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. I ...

Core Viewpoint - Walgreens Boots Alliance Inc (WBA) has been experiencing stagnant stock performance, particularly following the announcement of a $10 billion deal to take the company private by Sycamore Partners, with the stock currently priced at $11.21 [1] Group 1: Stock Performance - WBA has been identified as the worst-performing stock in the S&P 500 Index for the month of June over the past decade, averaging a loss of 3.7% and finishing lower 80% of the time [2] - The average return for WBA in June is -3.69%, with a median return of -1.63%, and only 20% of the time has it posted a positive return [3] Group 2: Analyst Sentiment - Among the 15 analysts covering WBA, only two have a "buy" rating, while 11 maintain a "hold" rating, indicating potential for downgrades that could negatively impact the stock [4] - The current call/put volume ratio for WBA is 4.57, which is higher than 84% of readings from the past year, suggesting a high level of optimism in the options market [4] Group 3: Options Market - The Schaeffer's Volatility Index (SVI) for WBA is at 23%, ranking in the low 12th percentile of its annual range, indicating that options traders are expecting low volatility [5] - Historically, WBA has outperformed these low volatility expectations, as reflected in its Schaeffer's Volatility Scorecard (SVS) score of 81 out of 100 [5]

Company Overview - Astellas Pharma Inc. is part of the Medical sector, which includes 997 individual stocks and currently holds a Zacks Sector Rank of 4 [2] - The company is classified under the Medical - Drugs industry, which consists of 161 companies and is ranked 52 in the Zacks Industry Rank [6] Performance Analysis - Astellas Pharma Inc. has a Zacks Rank of 1 (Strong Buy), indicating a positive outlook based on earnings estimates and revisions [3] - Over the past 90 days, the Zacks Consensus Estimate for Astellas Pharma's full-year earnings has increased by 20.7%, reflecting improved analyst sentiment [4] - Year-to-date, Astellas Pharma has returned approximately 0.3%, outperforming the Medical sector, which has seen an average loss of 7.1% [4] Comparative Analysis - AtriCure, another stock in the Medical sector, has a year-to-date return of 7% and a Zacks Rank of 2 (Buy) [5] - The Medical - Products industry, where AtriCure is categorized, has a ranking of 147 and has increased by 3.8% since the beginning of the year [7] - In contrast, Astellas Pharma's industry has underperformed slightly, with an average loss of 2% year-to-date [6]

Company Overview - Bio-Path Holdings, Inc. is a biotechnology company focused on developing targeted nucleic acid cancer and obesity drugs using its proprietary DNAbilize antisense RNAi nanoparticle technology [1][3] - The company has a pipeline of RNAi nanoparticle drugs that can be administered via intravenous infusion [3] Product Pipeline - The lead product candidate, prexigebersen (BP1001), is currently in a Phase 2 study for blood cancers [3] - BP1001-A, a modified version of prexigebersen, is in a Phase 1/1b study for solid tumors and is also being evaluated for obesity and related metabolic diseases in Type 2 diabetes patients [3] - The second product, BP1002, targets the Bcl-2 protein and is being evaluated for blood cancers and solid tumors, including acute myeloid leukemia [3] - An IND application for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide, is expected to be filed [3] Upcoming Events - The company will host a live conference call and audio webcast on May 29, 2025, at 8:30 a.m. ET to provide a comprehensive business overview [1]

Group 1 - MediWound reported a quarterly loss of $0.07 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.65, representing an earnings surprise of 89.23% [1] - The company posted revenues of $3.96 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 22.39%, and down from $4.96 million a year ago [2] - MediWound shares have increased approximately 17.3% since the beginning of the year, outperforming the S&P 500's gain of 1% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.67 on revenues of $5.74 million, and for the current fiscal year, it is -$2.84 on revenues of $24.36 million [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 21% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Company Overview - Alignment Healthcare (ALHC) is currently ranked 5 in the Zacks Sector Rank within the Medical group, which consists of 999 companies [2] - The Zacks Rank system, which focuses on earnings estimates and revisions, has assigned ALHC a Zacks Rank of 2 (Buy) [3] Performance Metrics - The Zacks Consensus Estimate for ALHC's full-year earnings has increased by 34.1% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [4] - Year-to-date, ALHC has returned 44.4%, significantly outperforming the average loss of 4.8% in the Medical group [4] Industry Context - Alignment Healthcare operates within the Medical Services industry, which includes 58 stocks and currently ranks 52 in the Zacks Industry Rank; this industry has seen an average loss of 1.9% this year, highlighting ALHC's relative strength [6] - In contrast, BridgeBio Pharma (BBIO), another outperforming stock in the Medical sector, belongs to the Medical - Generic Drugs industry, which has a lower ranking (198) and has declined by 15.1% this year [6] Future Outlook - Investors interested in Medical stocks should monitor Alignment Healthcare and BridgeBio Pharma for potential continued strong performance [7]

Core Insights - Rite Aid is closing additional stores and transferring business to competitors as it faces financial difficulties, having filed for bankruptcy for the second time [1][3] - The company plans to shut down 210 stores, with over 70 closures in Pennsylvania alone [1] - Rite Aid has reached agreements to sell prescription files for more than 1,000 pharmacy locations to major competitors like CVS and Walgreens [2] Group 1: Bankruptcy and Store Closures - Rite Aid filed for Chapter 11 bankruptcy protection on May 5, 2023, less than a year after emerging from a previous restructuring effort [3] - The company previously attempted to reduce approximately $2 billion in debt and closed around 850 stores [3] - Rite Aid's current bankruptcy filing indicates ongoing financial struggles, leading to the decision to close additional locations [1][3] Group 2: Market Adaptation and Consumer Behavior - The company is adapting its offerings and pricing strategies to cater to paycheck-to-paycheck consumers, acknowledging the economic situation of its shoppers [5] - Rite Aid's difficulties are partly attributed to lower-income shoppers' trade-down behavior, with a shift towards purchasing household goods from more affordable retailers [6] - Research indicates that a significant majority of consumers change their purchasing behaviors during economic distress, with only 16% stating that perceived inflation has not affected their consumption [7]